[Translated article] Safety of excipients in pediatric medications: impact on child health.

Farm HospJun 24, 2026 (epub)
Clinical ResearchPediatrics

Leonel Silva-Chocoteco, Monserratt Abud-González, Cesar Ricardo Cortez-Álvarez et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the safety of excipients in pediatric medications, highlighting their potential toxicity in children. The review identified 54 excipients with documented risks, including hepatic, renal, and neurological toxicity. The findings emphasize the need for improved safety evaluations and age-specific formulations due to children's heightened vulnerability.

Key findings

  • Fifty-four excipients with potential toxicity in children were identified and classified into four functional groups.
  • Notable adverse effects include hepatic, renal, and neurological toxicity, as well as hypersensitivity reactions.
  • A significant limitation is the lack of specific data for the pediatric population.

Why it matters

Understanding the safety of excipients is crucial for pediatric care, as children are more susceptible to adverse effects. This knowledge can guide healthcare professionals in making informed decisions regarding medication formulations.

Source

Published in Farm Hosp. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.